Healx is an AI-powered drug discovery company specializing in rare and neurological diseases. The company combines artificial intelligence with deep pharmacological expertise to identify new therapeutic uses for existing drugs (drug repurposing) and to advance novel treatments for rare diseases. Healx's mission is to accelerate the development of treatments for the 300 million people worldwide living with rare diseases["@healx"].
The company has established a particular focus on neurological and neurodegenerative conditions, including [Parkinson's disease, [Alzheimer's disease, and rare neurological disorders. Their AI platform, Healnet, analyzes massive datasets to identify disease-treatment connections that would be difficult or impossible for humans to discover through traditional research methods.
AI Technology Platform
Healnet AI Platform
Healnet is Healx's proprietary AI platform that integrates multiple data sources and machine learning models:
Data Sources:
Disease biology databases
Drug pharmacology data
Genomic information
Clinical trial data
Scientific literature
Patient-level data
...
Healx
Company: Healx Ltd.
Headquarters: Cambridge, United Kingdom
Founded: 2014
Funding: $47 million (Series B, 2022)
Ownership: Private
Overview
Mermaid diagram (expand to render)
Healx is an AI-powered drug discovery company specializing in rare and neurological diseases. The company combines artificial intelligence with deep pharmacological expertise to identify new therapeutic uses for existing drugs (drug repurposing) and to advance novel treatments for rare diseases. Healx's mission is to accelerate the development of treatments for the 300 million people worldwide living with rare diseases["@healx"].
The company has established a particular focus on neurological and neurodegenerative conditions, including [Parkinson's disease, [Alzheimer's disease, and rare neurological disorders. Their AI platform, Healnet, analyzes massive datasets to identify disease-treatment connections that would be difficult or impossible for humans to discover through traditional research methods.
AI Technology Platform
Healnet AI Platform
Healnet is Healx's proprietary AI platform that integrates multiple data sources and machine learning models:
Data Sources:
Disease biology databases
Drug pharmacology data
Genomic information
Clinical trial data
Scientific literature
Patient-level data
AI Capabilities:
Knowledge graph construction
Predictive modeling for drug-disease matching
Target identification
Biomarker discovery
Clinical trial optimization
Approach: Drug Repurposing
Healx specializes in drug repurposing (also called drug repositioning) - finding new uses for existing drugs:
Advantages:
Reduced development time (often 3-5 years vs 10-15 for new drugs)
Lower development costs
Known safety profiles
Established manufacturing processes
Faster path to patients
Neurological Disease Programs
Healx has established a significant pipeline of programs targeting neurological conditions:
Parkinson's disease Disease
| Program | Approach | Stage | Partner | |---------|----------|-------|---------| | HL-001 | Drug repurposing | Preclinical | Founded by The Michael J. Fox Foundation | | [GBA](/entities/gba)-PD program | Genetic targeting | Discovery | [Parkinson's disease](/diseases/parkinsons-disease) UK |
HL-001 (Parkinson's disease Disease)
Healx's lead Parkinson's disease program leverages their AI platform to identify existing drugs that could be repurposed:
Approach: Drug repurposing for genetic subtypes of PD
Target: GBA (glucocerebrosidase) mutation carriers
Rationale: GBA mutations are the most common genetic risk factor for PD
Status: Preclinical validation
Alzheimer's disease Disease
| Program | Approach | Stage | |---------|----------|-------| | HL-003 | Multi-target approach | Discovery | | Combination therapy program | Drug combinations | Discovery |
Rare Neurological Conditions
Healx has programs in several rare neurological conditions:
Rett Syndrome: Drug repurposing program (collaboration with Rett Syndrome Research Trust)
Fragile X Syndrome: Early discovery
Dravet Syndrome: Preclinical validation
tuberous Sclerosis Complex: Discovery
Business Model
Partnerships
Healx operates through a combination of internal programs and partnerships:
Academic Partnerships:
University of Cambridge
University College London
Barcelona Beta Brain Research Center
Charité - Universitätsmedizin Berlin
Patient Advocacy Partnerships:
The Michael J. Fox Foundation (Parkinson's disease)
[Parkinson](/diseases/parkinsons-disease)'s disease UK
Rare disease patient organizations
Pharmaceutical Partnerships:
Pharma collaborations for specific programs
Funding History
| Year | Round | Amount | Investors | |------|-------|--------|-----------| | 2022 | Series B | $47M | Accel, Better Ventures, b10 | | 2020 | Series A | $14M | Angel CoFund, Jonathan Milner | | 2018 | Seed | $3.5M | Various angels |
Technology Differentiation
Why AI for Rare Disease Drug Discovery
Scale: AI can analyze millions of drug-disease relationships in hours
Cost: Reduces experimental screening costs
Speed: Accelerates identification of candidates
Novelty: Finds connections humans might miss
Competitive Advantages
Proprietary dataset: Years of curated rare disease data
Expert team: Combined expertise in AI, pharmacology, and rare diseases
Clinical network: Access to patient populations and clinical experts
Track record: Demonstrated success in identifying clinical candidates
Impact and Goals
Patient Impact
Healx's mission is to bring treatments to patients faster:
Goal: 100 rare disease treatments in development by 2025
Current: 20+ active programs across multiple disease areas
Approach: Focus on indications with high unmet need and clear regulatory pathways
Neurological Focus
The company has made neurological diseases a strategic priority:
High unmet need in neurodegenerative diseases
Strong scientific rationale for drug repurposing
Active patient advocacy community
Clear regulatory pathways (orphan drug designations)